Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
Search
Home
Categories
DMD
Research
Press Releases
Approved Treatments
Editorials
Family Stories
Cures
WhatsApp Channel
About Us
Contact
More
Search
Home
Tags
FDA
FDA
Press Releases
Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
Press Releases
FDA: ‘Elevidys Gene Therapy Will Continue to Be Used in Ambulatory DMD Patients’
Press Releases
FDA Investigating Death of 8-Year-Old Brazilian Boy Who Received Elevidys
Press Releases
The FDA Designates PBGENE-DMD as an Orphan Drug by Precision BioSciences to Treat Duchenne Muscular Dystrophy
Editorials
Vyondys 53: What Does FDA Rejection Letter Mean?
Press Releases
Capricor Therapeutics Announces BMD Orphan Drug Designation and DMD Program Regulatory Development for Deramiocel (CAP-1002)
Press Releases
Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
DMD
Explore Of 5 Phases In Drug Development
Press Releases
Solid Biosciences Plans to Request a Meeting with the FDA in mid-2025 to Discuss Potential Accelerated Approval Pathways for SGT-003
1
2
3
Page 1 of 3
Popular
Frequently Asked Questions About Elevidys Used for Duchenne Muscular Dystrophy
DMD Warrior
-
December 26, 2024
Must Read
Editorials
Accredited Duchenne Centers (ADC) Aims to Provide Uniform and Up-to-date Care for All People Living with Duchenne Muscular Dystrophy
Research
RGX-202 Gene Therapy Phase 3 Clinical Trial Begins
Research
Entrada Therapeutics Begins Clinical Trials in Europe for Exon 44 and Exon 45 Skipping Therapies